Companies › Nanjing Sanhome Pharmaceutical
4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SH-1028 tablets EGFR tyrosine kinase inhibitor | EGFR | Phase 3 | Non-small Cell Lung Cancer | Feb 2028 |
| SH006 | – | Phase 1 | Liver Cancer | Dec 2026 |
| SH009 | – | Phase 1 | Liver Cancer (Locally Advanced or Metastatic) | Dec 2026 |
| SH3765 unclear mechanism | – | Phase 1 | HR+ / HER2- Advanced Breast Cancer | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07390838 | SH009 | Phase 1 | Liver Cancer (Locally Advanced or Metastatic) | Oncology | Dec 2026 |
| NCT07362264 | SH006 | Phase 1 | Liver Cancer | Oncology | Dec 2026 |
| NCT07557004 | SH3765 | Phase 1 | HR+ / HER2- Advanced Breast Cancer | Oncology | Jun 2027 |
| NCT06080776 | SH-1028 tablets | Phase 3 | Non-small Cell Lung Cancer | Oncology | Feb 2028 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Jiangsu Alphamab Biopharmaceuticals Jiangsu Aosaikang Pharmaceutical ArriVent BioPharma HC Biopharma Wayshine Biopharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.